| 33.31 -0.55 (-1.62%) | 07-29 13:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 45.48  |
1-year : | 49.97 |
| Resists | First : | 38.94 |
Second : | 42.79 |
| Pivot price | 36.74 |
|||
| Supports | First : | 32.72 |
Second : | 27.22 |
| MAs | MA(5) : | 34.44 |
MA(20) : | 37.34 |
| MA(100) : | 33.56 |
MA(250) : | 32.92 |
|
| MACD | MACD : | -0.2 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 8.3 |
D(3) : | 6.5 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 43.15 | Low : | 22.95 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VKTX ] has closed above bottom band by 7.2%. Bollinger Bands are 21.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.91 - 35.1 | 35.1 - 35.26 |
| Low: | 32.14 - 32.41 | 32.41 - 32.62 |
| Close: | 33.46 - 33.86 | 33.86 - 34.19 |
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Tue, 28 Jul 2026
Viking Therapeutics (VKTX) Q2 Earnings Preview: Market Pricing in Continued Losses Amid Mixed Guru Activity - GuruFocus
Tue, 28 Jul 2026
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView
Tue, 28 Jul 2026
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Mon, 27 Jul 2026
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness - Moomoo
Thu, 23 Jul 2026
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market - Yahoo! Finance Canada
Thu, 23 Jul 2026
Dorothy Gemmell Joins Viking Board After 25+ Years in Healthcare - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 116 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 64.5 (%) |
| Shares Short | 23,160 (K) |
| Shares Short P.Month | 23,320 (K) |
| EPS | -4.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.6 % |
| Return on Equity (ttm) | -70.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -340 (M) |
| Levered Free Cash Flow | -177 (M) |
| PE Ratio | -8.04 |
| PEG Ratio | 0 |
| Price to Book value | 7.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|